Status: Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.
Participants needed: 202
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: EMD Serono Research & Development Institute, Inc.Updated: Jul 2, 2026Locations: 9
Eligibility criteria
Vaccinations are up to date according to local guidelines/recommendations. Recom... [+7]
Participants with primary diagnosis of autoimmune rheumatic disease (e.g., syste... [+6]